Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

Completed · Not applicable

Conditions studied: HIV

In brief

The purpose of this study is to determine whether or not adding Raltegravir to a fully suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic inflammation and increase the t-lymphocyte memory cell pool.

Key facts

Study ID

NCT00738569

Run by

National Jewish Health

People needed

30

Starts

2008-07-01

Expected to finish

2011-02-01

Last updated by the study team

2021-01-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• At least 18 years of age
• HIV-positive by Western blot or viral load
• Viral load < 400 copies/ml
• CD4+ T-lymphocyte count less than 350 cells/mm3 or change in CD4+ T-lymphocyte count < 100 cells/mm3 for at least one year on stable HAART with viral load < 400 copies/ml for the same period of time

You may not qualify if…

• CD4+ T-lymphocyte count greater than or equal to 350 cells/mm3 or rise in CD4+ T-lymphocyte count greater than or equal to 100 cells/mm3 within one year of study entry
• Viral load > 400 copies/ml
• Allergy or resistance to raltegravir

Where it is running

• National Jewish Health — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.